APA (7th ed.) Citation

T, D., D, S., C, D., D, M., C, K., M, G., . . . H, B. (2020). Reply to Rappaport et al: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19. American journal of respiratory and critical care medicine, 202(12), 1733. https://doi.org/10.1164/rccm.202007-2913LE

Chicago Style (17th ed.) Citation

T, Dutt, Simcox D, Downey C, McLenaghan D, King C, Gautam M, Lane S, and Burhan H. "Reply to Rappaport Et Al: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19." American Journal of Respiratory and Critical Care Medicine 202, no. 12 (2020): 1733. https://doi.org/10.1164/rccm.202007-2913LE.

MLA (9th ed.) Citation

T, Dutt, et al. "Reply to Rappaport Et Al: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19." American Journal of Respiratory and Critical Care Medicine, vol. 202, no. 12, 2020, p. 1733, https://doi.org/10.1164/rccm.202007-2913LE.